(Q38896842)

7 September 2017

Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages (English)

1 reference

7 September 2017

0 references

1 reference

4

1 reference

7 September 2017

Yun Shi

1

1 reference

7 September 2017

Xuejun Fan

2

1 reference

7 September 2017

Hui Deng

3

1 reference

7 September 2017

Michael Rycyzyn

5

1 reference

7 September 2017

Robert E Jordan

6

1 reference

7 September 2017

William R Strohl

7

1 reference

7 September 2017

Quanming Zou

8

1 reference

7 September 2017

Ningyan Zhang

9

1 reference

7 September 2017

Zhiqiang An

10

1 reference

7 September 2017

language of work or name

English

0 references

publication date

20 March 2015

1 reference

7 September 2017

Journal of Immunology

1 reference

7 September 2017

194

1 reference

7 September 2017

9

1 reference

7 September 2017

4379-4386

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

7 September 2017

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

The function of Fcγ receptors in dendritic cells and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Engineered antibody Fc variants with enhanced effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Bone Marrow-Derived Macrophages (BMM): Isolation and Applications

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

FcgammaRIV: a novel FcR with distinct IgG subclass specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Identification of CD16-2, a novel mouse receptor homologous to CD16/Fc gamma RIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Fcγ receptors in cancer and infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Fc receptors and their interactions with immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Experimental Antibody Therapy of Liver Metastases Reveals Functional Redundancy between Fc RI and Fc RIV

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1402891

21 January 2018

Identifiers

DOI

10.4049/JIMMUNOL.1402891

1 reference

7 September 2017

1 reference